EPA:IPN - Euronext Paris - Matif - FR0010259150 - Common Stock - Currency: EUR
EPA:IPN (3/7/2025, 7:00:00 PM)
110
-2 (-1.79%)
The current stock price of IPN.PA is 110 EUR. In the past month the price decreased by -9.54%. In the past year, price increased by 6.08%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 67 | 760.43B | ||
LLY.DE | ELI LILLY & CO | 66.98 | 760.15B | ||
ZEG.DE | ASTRAZENECA PLC | 21.82 | 446.45B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.81 | 372.31B | ||
1JNJ.MI | JOHNSON & JOHNSON | 16.61 | 367.98B | ||
NOV.DE | NOVO NORDISK A/S-B | 26.21 | 355.97B | ||
SNW.DE | SANOFI | 14.32 | 275.64B | ||
SAN.PA | SANOFI | 14.27 | 274.84B | ||
1SAN.MI | SANOFI | 14.19 | 273.18B | ||
6MK.DE | MERCK & CO. INC. | 12.64 | 224.82B | ||
1MRKX.MI | MERCK & CO. INC. | 12.47 | 221.79B | ||
PFE.DE | PFIZER INC | 8.69 | 140.81B |
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France and currently employs 5,325 full-time employees. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
IPSEN
65 Quai Georges Gorse
Boulogne-Billancourt ILE-DE-FRANCE FR
Employees: 5325
Company Website: https://www.ipsen.com/
Investor Relations: https://www.ipsen.com/investors/
Phone: 33158335000
The current stock price of IPN.PA is 110 EUR. The price decreased by -1.79% in the last trading session.
The exchange symbol of IPSEN is IPN and it is listed on the Euronext Paris - Matif exchange.
IPN.PA stock is listed on the Euronext Paris - Matif exchange.
19 analysts have analysed IPN.PA and the average price target is 127.81 EUR. This implies a price increase of 16.19% is expected in the next year compared to the current price of 110. Check the IPSEN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IPSEN (IPN.PA) has a market capitalization of 9.22B EUR. This makes IPN.PA a Mid Cap stock.
IPSEN (IPN.PA) currently has 5325 employees.
IPSEN (IPN.PA) has a support level at 109.3 and a resistance level at 111.43. Check the full technical report for a detailed analysis of IPN.PA support and resistance levels.
The Revenue of IPSEN (IPN.PA) is expected to grow by 7.41% in the next year. Check the estimates tab for more information on the IPN.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IPSEN (IPN.PA) has a dividend yield of 1.25%. The yearly dividend amount is currently 1.21. Check the full fundamental report for a detailed analysis of IPN.PA dividend history, reliability and sustainability.
IPSEN (IPN.PA) will report earnings on 2025-04-16.
The PE ratio for IPSEN (IPN.PA) is 15.92. This is based on the reported non-GAAP earnings per share of 6.91 and the current share price of 110 EUR. Check the full fundamental report for a full analysis of the valuation metrics for IPN.PA.
ChartMill assigns a technical rating of 2 / 10 to IPN.PA. When comparing the yearly performance of all stocks, IPN.PA turns out to be only a medium performer in the overall market: it outperformed 61.26% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to IPN.PA. Both the profitability and the financial health of IPN.PA get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months IPN.PA reported a non-GAAP Earnings per Share(EPS) of 6.91. The EPS decreased by -10.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 10.85% | ||
ROA | 8.97% | ||
ROE | 13.82% | ||
Debt/Equity | 0.09 |
ChartMill assigns a Buy % Consensus number of 67% to IPN.PA. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 7.55% and a revenue growth 7.41% for IPN.PA